Casale TB, et al. – This study was formulated to analyze factors that predict response to omalizumab to facilitate selection of patients most likely to derive the greatest clinical benefit from therapy. Baseline blood eosinophil levels and/or clinical markers of asthma severity predicted response to omalizumab in patients with allergic asthma.